Rational design and eco-friendly one-pot multicomponent synthesis of novel ethylidenehydrazineylthiazol-4(5H)-ones as potential apoptotic inducers targeting wild and mutant EGFR-TK in triple negative breast cancer

Bioorg Chem. 2024 Jan:142:106936. doi: 10.1016/j.bioorg.2023.106936. Epub 2023 Oct 24.

Abstract

A novel series of ethylidenehydrazineylthiazol-4(5H)-ones were synthesized using various eco-friendly one-pot multicomponent synthetic techniques. The anticancer activity of compounds (4a-m) was tested against 11 cancer cell lines. While the IC50 of all compounds was evaluated against the most sensitive cell lines (MDA-MB-468 and FaDu). Our SAR study pinpointed that compound 4a, having a phenyl substituent, exhibited a significant growth inhibition % against all cancer cell lines. The frontier anticancer candidates against the MDA-MB-468 were also examined against the wild EGFR (EGFR-WT) and mutant EGFR (EGFR-T790M) receptors. Most of the synthesized compounds exhibited a higher inhibitory potential against EGFR-T790M than the wild type of EGFR. Remarkably, compound 4k exhibited the highest inhibitory activity against both EGFR-WT and EGFR-T790M with IC50 values (0.051 and 0.021 µM), respectively. The pro-apoptotic protein markers (p53, BAX, caspase 3, caspase 6, caspase 8, and caspase 9) and the anti-apoptotic key marker (BCL-2) were also measured to propose a mechanism of action for the compound 4k as an apoptotic inducer for MDA-MB-468. Investigation of the cell cycle arrest potential of compound 4k was also conducted on MDA-MB-468 cancer cells. We also evaluated the inhibitory activities of compounds (4a-m) against both EGFR-WT and EGFR-T790M using two different molecular docking processes.

Keywords: Apoptosis; EGFR inhibitors; Eco-friendly one-pot multicomponent synthesis; Ethylidenehydrazineylthiazol-4(5H)-ones; Rational design.

MeSH terms

  • Antineoplastic Agents*
  • Apoptosis
  • Cell Line, Tumor
  • Cell Proliferation
  • Drug Screening Assays, Antitumor
  • ErbB Receptors
  • Humans
  • Lung Neoplasms*
  • Molecular Docking Simulation
  • Molecular Structure
  • Mutation
  • Protein Kinase Inhibitors
  • Structure-Activity Relationship
  • Triple Negative Breast Neoplasms*

Substances

  • ErbB Receptors
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • EGFR protein, human